Stoke Therapeutics (NASDAQ:STOK) Rating Lowered to Hold at ValuEngine

Stoke Therapeutics (NASDAQ:STOK) was downgraded by ValuEngine from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, ValuEngine reports.

STOK has been the topic of a number of other reports. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Stoke Therapeutics in a research note on Tuesday, August 11th. Canaccord Genuity reaffirmed a “buy” rating and issued a $44.00 price target on shares of Stoke Therapeutics in a research note on Thursday, July 9th. Zacks Investment Research lowered Stoke Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 14th. Finally, BidaskClub raised Stoke Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 11th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $34.83.

Stoke Therapeutics stock opened at $34.09 on Tuesday. The stock has a market capitalization of $1.13 billion, a PE ratio of -18.94 and a beta of 0.36. Stoke Therapeutics has a 12 month low of $15.82 and a 12 month high of $35.00. The business has a 50 day simple moving average of $28.50 and a 200-day simple moving average of $24.94.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.39) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.04). Equities analysts forecast that Stoke Therapeutics will post -1.55 EPS for the current fiscal year.

In other Stoke Therapeutics news, COO Huw M. Nash sold 2,081 shares of the business’s stock in a transaction on Friday, August 28th. The stock was sold at an average price of $30.00, for a total transaction of $62,430.00. Following the transaction, the chief operating officer now owns 2,081 shares of the company’s stock, valued at $62,430. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Huw M. Nash sold 1,900 shares of the business’s stock in a transaction on Thursday, July 16th. The stock was sold at an average price of $25.06, for a total value of $47,614.00. Following the transaction, the chief operating officer now directly owns 1,900 shares in the company, valued at approximately $47,614. The disclosure for this sale can be found here. Insiders have sold 46,053 shares of company stock worth $1,319,305 in the last three months. 54.60% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in STOK. Ameritas Investment Partners Inc. lifted its stake in shares of Stoke Therapeutics by 94.5% in the 1st quarter. Ameritas Investment Partners Inc. now owns 1,480 shares of the company’s stock valued at $34,000 after purchasing an additional 719 shares during the last quarter. Legal & General Group Plc lifted its stake in shares of Stoke Therapeutics by 45.3% in the 1st quarter. Legal & General Group Plc now owns 2,618 shares of the company’s stock valued at $60,000 after purchasing an additional 816 shares during the last quarter. BNP Paribas Arbitrage SA lifted its stake in shares of Stoke Therapeutics by 313.6% in the 1st quarter. BNP Paribas Arbitrage SA now owns 5,220 shares of the company’s stock valued at $120,000 after purchasing an additional 3,958 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Stoke Therapeutics by 82.3% in the 1st quarter. JPMorgan Chase & Co. now owns 5,505 shares of the company’s stock valued at $126,000 after purchasing an additional 2,486 shares during the last quarter. Finally, Deutsche Bank AG lifted its stake in shares of Stoke Therapeutics by 81.8% in the 1st quarter. Deutsche Bank AG now owns 5,910 shares of the company’s stock valued at $135,000 after purchasing an additional 2,659 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc has a partnership with Invitae Corporation to offer epilepsy panel testing.

Featured Article: What is the QQQ ETF?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Stoke Therapeutics (NASDAQ:STOK)

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.